An Extension Study to Provide Continued Bevacizumab Therapy to Participants With Solid Tumors Who Were Previously Enrolled in a Roche/Genentech Sponsored Study

  • Cancer
  • Tumor
  • Neoplasms
Please note that the recruitment status of the trial at your site may differ from the overall study status because some study sites may recruit earlier than others.
Trial Status:

Completed

This trial runs in
Cities
  • A Coruña
  • Adana
  • andalucia
  • Barakaldo
  • Barnaul
  • Besançon
  • Bilbo
  • bodelwyddan
  • Bologna
  • Brindisi
  • Budapest
  • Burgos
  • Cambridge
  • Catania
  • Ciudad de México
  • Cluj-Napoca
  • Dechy
  • Den Haag
  • Dijon
  • Eskilstuna
  • Frankfurt am Main
  • Goiás
  • Goyang-si
  • Großhansdorf
  • Iași
  • Irkutsk Oblast
  • Jaén
  • Johannesburg
  • kaluga-oblast
  • Košický kraj
  • leon-de-los-aldama
  • Lille
  • Lombardia
  • Lyon
  • Madrid
  • Manchester
  • Milano
  • Monza
  • Moscow
  • Moscow Oblast
  • Málaga
  • Napoli
  • Nijmegen
  • oaxaca-de-juarez
  • olomouc-9
  • Pisa
  • Prato
  • Rio Grande do Sul
  • Roma
  • san-fermo-della-battaglia
  • Seoul
  • Sofia
  • Strasbourg
  • São Paulo
  • Tallinn
  • Torino
  • Toronto
  • Toulouse
  • Ufa
  • Ulsan
  • Umeå
  • upper-austria
  • València
  • Örebro län
Trial Identifier:

NCT01588184 2011-002009-31 MO25757

      Show trial locations

      The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical trial see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.

      The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

      Results Disclaimer

      Trial Summary

      This single-arm, open-label, multicenter extension study will provide continued bevacizumab therapy to participants with solid tumors who were previously enrolled in a Roche/Genentech sponsored study and who derived benefit from the bevacizumab therapy. Participants will receive the same dose and regimen of bevacizumab as used in the previous parent trial and continue this treatment until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.

      Hoffmann-La Roche Sponsor
      Phase 4 Phase
      NCT01588184,MO25757,2011-002009-31 Trial Identifier
      Bevacizumab Treatments
      Neoplasms Condition
      Official Title

      A Single Arm, Open Label Multicentre Extension Study of Bevacizumab in Patients With Solid Tumours on Study Treatment With Bevacizumab, at the End of A F. Hoffmann-La Roche and/or Genentech Sponsored Study

      Eligibility Criteria

      All Gender
      ≥18 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Participant is treated with bevacizumab at the end of the Roche/Genentech sponsored parent trial and continues to have benefit as judged by the investigator
      • Eligible for continuation of bevacizumab treatment at the end of a parent trial, according to parent trial protocol
      • Able to comply with this extension study protocol (MO25757)
      Exclusion Criteria
      • Evidence of disease progression assessed according to parent trial protocol during the screening phase for this extension study
      • Evidence of any adverse event potentially attributable to bevacizumab, for which the local label recommends permanent discontinuation
      • A treatment interruption with bevacizumab of more than 42 days since the last administration of bevacizumab in the parent trial
      • Evidence of any other disease that would put the participant at high risk for treatment-related complications

      About Clinical Research

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

      Find out now